A Phase 1b Study of GDC-0449 Following Autologous Transplantation in Patients With High Risk First Remission or Relapsed Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2014
At a glance
- Drugs Vismodegib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 01 Aug 2013 Planned End Date changed from 1 Mar 2011 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 01 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Feb 2013 Planned number of patients changed from 35 to 38 as reported by ClinicalTrials.gov.